Fragrance active stabilization and controlled release in topical formulations
A cutting-edge microencapsulation technology using hollow yeast cell wall particles to stabilize volatile scent compounds and enable controlled release in topical formulations. This approach improves fragrance stability and supports sustained scent release, enhancing performance in various consumer care applications.
Overview
This solution presents a novel approach to fragrance stabilization and controlled release in topical formulations using proprietary microencapsulation technology. The core innovation involves hollow yeast cell wall particles (YPs) that encapsulate volatile scent compounds, such as terpenoids, to protect and stabilize them. This technology ensures improved fragrance stability and allows for a prolonged and consistent scent release, making it ideal for consumer care applications.
Technical specifications
Key features:
- Utilizes hollow yeast cell wall particles for high-capacity encapsulation.
- Offers a stimuli-mediated release system to tailor release profiles for rapid or sustained performance.
- Supports self-emulsifying systems suitable for both hydrophobic and aqueous formulations.
- Demonstrates robust performance in stabilizing volatile compounds and improving formulation stability.
The system can be customized to meet specific product profiles, providing flexibility in addressing common limitations in topical delivery systems, such as short scent duration and phase instability.
Technology readiness level
Currently at Technology Readiness Level 4, this solution has achieved significant laboratory validation. Phase I of development involves preparing samples and characterizing encapsulation efficiency and release kinetics. Successful candidates will progress to prototype development in Phase II, where they will be benchmarked against commercial products for performance validation.
About University of Massachusetts Medical School
A public academic health sciences center within the University of Massachusetts system, it combines medical education, graduate training, and patient care with a strong research enterprise. Close integration with a major hospital system enables access to diverse patient populations, clinical data, and translational infrastructure, supporting industry‑sponsored studies and real‑world evaluation. Co‑located research core facilities and centralized contracting, IRB, and compliance support streamline collaboration, from early discovery through multicenter trials. The institution attracts significant NIH funding and competitive awards from other federal agencies and foundations. A dedicated technology transfer office manages IP, material transfer and licensing, and supports startup formation and corporate research agreements.
delivered to your inbox.